CA2674888A1 - Anti-ige vaccines - Google Patents

Anti-ige vaccines Download PDF

Info

Publication number
CA2674888A1
CA2674888A1 CA002674888A CA2674888A CA2674888A1 CA 2674888 A1 CA2674888 A1 CA 2674888A1 CA 002674888 A CA002674888 A CA 002674888A CA 2674888 A CA2674888 A CA 2674888A CA 2674888 A1 CA2674888 A1 CA 2674888A1
Authority
CA
Canada
Prior art keywords
seq
ige
antigenic
amino acid
dogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002674888A
Other languages
English (en)
French (fr)
Inventor
Mohamad Ali Morsey
Michael George Sheppard
David Walter Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis P LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2674888A1 publication Critical patent/CA2674888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002674888A 2000-08-30 2001-08-28 Anti-ige vaccines Abandoned CA2674888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22898900P 2000-08-30 2000-08-30
US60/228,989 2000-08-30
CA002356124A CA2356124A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002356124A Division CA2356124A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Publications (1)

Publication Number Publication Date
CA2674888A1 true CA2674888A1 (en) 2002-02-28

Family

ID=22859366

Family Applications (5)

Application Number Title Priority Date Filing Date
CA002674888A Abandoned CA2674888A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674837A Expired - Fee Related CA2674837C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674838A Expired - Fee Related CA2674838C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA002356124A Abandoned CA2356124A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674885A Expired - Fee Related CA2674885C (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA2674837A Expired - Fee Related CA2674837C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674838A Expired - Fee Related CA2674838C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA002356124A Abandoned CA2356124A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674885A Expired - Fee Related CA2674885C (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Country Status (4)

Country Link
US (5) US6887472B2 (enExample)
EP (5) EP1195161A3 (enExample)
JP (5) JP2002281984A (enExample)
CA (5) CA2674888A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195161A3 (en) * 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccines
ES2329453T3 (es) * 2001-05-15 2009-11-26 Ortho Mcneil Janssen Pharm Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas.
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
JP2006510588A (ja) * 2002-09-05 2006-03-30 レジステンシア ファーマシューティカルズ アーベー アレルギーワクチン
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
CN102584997A (zh) * 2002-11-08 2012-07-18 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CN102702359A (zh) 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
JP4520923B2 (ja) * 2005-09-28 2010-08-11 本田技研工業株式会社 エンジン始動装置
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
EP2865389A1 (en) * 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
AU2013204233B2 (en) * 2008-12-09 2015-06-25 Pfizer Vaccines Llc IgE CH3 peptide vaccine
WO2010097012A1 (en) * 2009-02-25 2010-09-02 Tsewen Chang ANTI-CεmX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
CA2800774A1 (en) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
KR101163472B1 (ko) * 2010-06-08 2012-07-18 기아자동차주식회사 자동차의 오프닝 웨더스트립 고정구조
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013158274A1 (en) 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
CN102660569B (zh) * 2012-04-21 2013-11-06 大连理工大学 一种重组人IgE受体蛋白的制备方法及应用
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
EP3156423B1 (en) * 2014-06-11 2025-02-19 Riken Multiplex alloantigenic peptide
US10293059B2 (en) * 2015-04-09 2019-05-21 Cornell University Gene therapy to prevent reactions to allergens
CN111741768B (zh) 2017-10-31 2024-12-27 合一生技股份有限公司 治疗IgE介导的过敏性疾病
US11857623B2 (en) * 2020-08-07 2024-01-02 King Abdulaziz University Pan-antiallergy vaccine
KR20240091042A (ko) * 2021-10-29 2024-06-21 롱바이오 파마 (수조우) 컴퍼니 리미티드 분리된 항원 결합 단백질 및 이의 용도
CN115873867B (zh) * 2022-09-28 2023-06-23 云南省农业科学院农业环境资源研究所 一种抗稻瘟病基因Pi69及其编码蛋白与应用
CN120271714A (zh) * 2022-12-07 2025-07-08 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN118878689B (zh) * 2024-08-28 2025-03-28 上海索莱宝生化科技有限公司 抗猪IgG抗体及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
JPS5668615A (en) 1979-11-09 1981-06-09 Eisai Co Ltd Ricin-containing agent for immunological enhancement
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
JPS63225397A (ja) 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
DE69231736T2 (de) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad Gerichtete abgabe von genen, die immunogene proteine kodieren
JPH06510752A (ja) * 1991-05-24 1994-12-01 ノースウエスタン・ユニバーシティ アレルギー治療のためのｐ物質の使用方法
DE69231385T2 (de) 1991-06-05 2001-04-12 The Board Of Regents Acting For And On Behalf Of The Unversity Of Michigan, Ann Arbor Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
US5629415A (en) * 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
JPH09169795A (ja) * 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンｅペプチド断片、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンｅ抗体の製造法
WO1997030156A2 (en) 1996-02-14 1997-08-21 Idexx Laboratories, Inc. NUCLEOTIDES AND PEPTIDES CORRESPONDING TO THE CANINE IgE HEAVY CHAIN CONSTANT REGION AND RELATED METHODS
EP0885244B2 (en) 1996-03-01 2008-04-16 Novartis AG Peptide immunogens for vaccination against and treatment of allergy
CA2263091A1 (en) 1996-08-30 1998-03-05 Exxonmobil Chemical Patents, Inc. Fluidized bed reactor and process
AU6532498A (en) 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
ES2234180T3 (es) * 1998-04-09 2005-06-16 Idexx Laboratories, Inc. Proteinas de fijacion especifica para el tratamiento de la alergia canina.
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
KR20010053162A (ko) * 1998-06-24 2001-06-25 알크-아벨로 에이/에스 액체 시료 중의 항체 검출 방법
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
CN1202125C (zh) * 1998-11-12 2005-05-18 卫生部上海生物制品研究所 肽免疫原、用其制成的治疗变态反应的疫苗及其制备方法
EP1195161A3 (en) * 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccines
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン

Also Published As

Publication number Publication date
US20020064525A1 (en) 2002-05-30
CA2356124A1 (en) 2002-02-28
EP1967206B1 (en) 2012-10-10
EP2065052A2 (en) 2009-06-03
US8273356B2 (en) 2012-09-25
US7897151B2 (en) 2011-03-01
EP2361635A3 (en) 2011-09-14
CA2674838C (en) 2014-02-18
CA2674837A1 (en) 2002-02-28
EP1195161A2 (en) 2002-04-10
EP1967205A3 (en) 2009-01-07
EP1967206A3 (en) 2009-01-07
CA2674837C (en) 2013-02-26
CA2674838A1 (en) 2002-02-28
CA2674885C (en) 2013-02-26
US20040146504A1 (en) 2004-07-29
JP2012161322A (ja) 2012-08-30
US20120321651A1 (en) 2012-12-20
EP2065052A3 (en) 2009-08-19
EP1195161A3 (en) 2002-07-24
US6887472B2 (en) 2005-05-03
EP1967205A2 (en) 2008-09-10
US20100113361A1 (en) 2010-05-06
JP2005102701A (ja) 2005-04-21
EP1967206A2 (en) 2008-09-10
EP2361635A2 (en) 2011-08-31
JP2013056904A (ja) 2013-03-28
JP2005043374A (ja) 2005-02-17
JP2002281984A (ja) 2002-10-02
EP1967205B1 (en) 2012-10-10
US20060062782A1 (en) 2006-03-23
CA2674885A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
US8273356B2 (en) Anti-IgE vaccines
US20080193439A1 (en) Non-Anaphylactogenic IgE Fusion Proteins
EP0666760B1 (en) VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS
TW201038284A (en) Treatment of insulin-resistant disorders
CA2134083C (en) Prophylactic and therapeutic agents for autoimmune diseases
US6113903A (en) Peptides and methods against diabetes
EP0697024A1 (en) Downregulation of allergen-specific immune response
WO1997032021A1 (en) Therapeutic agents based on monoclonal anti-idiotypic antibody 105ad7
EP1131354A1 (en) Contraceptive antibody vaccines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150129